Related Experiment Videos
[Clinical trial in a child population with bronchial asthma]
Insights
Hyposensitizing therapy for children with respiratory allergies showed significant clinical improvement after four years. Bronchial asthma saw the best benefits, while allergic conjunctivitis showed lesser improvement.
Area of Science:
- Pediatric Allergy and Immunology
- Immunotherapy Research
Background:
- Respiratory tract allergies and rhinoconjunctivitis are common in children.
- Hyposensitizing therapy is a treatment option for allergic diseases.
Purpose of the Study:
- To evaluate the long-term clinical efficacy of hyposensitizing therapy in children.
- To assess treatment outcomes after one and four years of therapy.
Main Methods:
- A review of 104 children undergoing hyposensitizing therapy.
- Therapy targeted common allergens: gramineae pollens, moulds, house dust, and Dermatophagoides mites.
- Clinical evaluations were performed after 1 year and 4 years of treatment.
Main Results:
- Significant clinical improvement was observed after four years of hyposensitizing therapy.
- Bronchial asthma demonstrated the most substantial benefits from the treatment.
- Allergic conjunctivitis showed less pronounced improvement compared to other conditions.
Conclusions:
- Long-term hyposensitizing therapy (4 years) is effective for pediatric respiratory allergies.
- Treatment outcomes vary by allergic condition, with bronchial asthma responding best.
- Further research may explore optimized protocols for specific allergic diseases.
Abstract:
A review of 104 children affected with respiratory tract allergies and or rhinoconjunctivitis in hyposensitizing therapy against gramineae pollens or moulds or house dust or Mix dermatophagoides is presented. Clinical evaluations were carried out in order to evaluate the clinical improvement after 1 year and after 4 years therapy (TIS). The best results were detected after 4 years obviously and in some allergic diseases more improvement were found from the authors. The most important results were obtained in bronchial asthma; the worse benefits were detected in allergic conjunctivitis.